Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8 PF-07321332 Boceprevir Intermediate

ʻO ka wehewehe pōkole:

Inoa Kemika: Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl] propanoate

CAS: 328086-60-8

Ke 'ano: Pada ke'oke'o i ka pauka ke'oke'o

Kūwaena o PF-07321332 Paxlovid (CAS 2628280-40-8) a me Boceprevir (CAS 394730-60-0)

ʻO ke kūlana kiʻekiʻe, ka hana kālepa

Inquiry: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Na Waiwai Kemika:

Inoa Kimia Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate
Nā huaʻōlelo like Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate;(αS,3S)-α-[(tert-Butyloxycarbonyl)aMino]-2-oxo-3-pyrrolidinepropanoic acid Methyl Ester;(S)-Methyl 2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate
Helu CAS 328086-60-8
Helu CAT RF-PI317
Kūlana Kūʻai Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram
ʻĀpana Molekala C13H22N2O5
Kaumaha Molecular 286.33
Brand Kemika Ruifu

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Keʻokeʻo a hiki i ka pauda keʻokeʻo
ʻIkepili A IR: E like me ka mea kuhikuhi
ʻIkepili B Manawa Hoʻopaʻa: E like me ka mea kuhikuhi
Nalo ma ka maloo ≤1.0%
Koena ma ka Ignition ≤0.20%
Hoʻokahi haumia ≤0.50%
Huina paumaele ≤2.0%
Nā Metala Kaumaha (Pb) ≤20ppm
Maemae ≥98.0%
Kūlana hoʻāʻo Kūlana ʻoihana
Hoʻohana Kūwaena o PF-07321332 Paxlovid (CAS 2628280-40-8) a me Boceprevir (CAS 394730-60-0)

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.

Pono:

1

FAQ:

Noi:

ʻO Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl] propanoate (CAS 328086-60-8) ka mea waena o PF-07321332 Paxlovid (CAS 2628280-40 -8) a me Boceprevir (CAS 394730-60-0).ʻO PF-07321332, ka mea koʻikoʻi o Paxlovid (PF-07321332 a me Ritonavir) he moho antiviral waha COVID-19 i hoʻokolokolo ʻia, he 3C-like protease (3CLPRO) i hiki i ka waha me nā hopena antiviral ikaika e kūʻē i ka maʻi SARS-CoV-2. a me COVID-19.Ma ka lā 6 o Nowemapa 2021, hoʻolaha ʻo Pfizer ua hōʻemi nui ʻo Paxlovid i ka haukapila a me ka make, e pili ana i kahi loiloi interim o ka Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study. o nā poʻe maʻi makua ʻole i hoʻokipa ʻia me COVID-19, ka poʻe i pilikia nui i ka holomua ʻana i ka maʻi koʻikoʻi.ʻO Boceprevir (EBP-520) he mea hoʻopaʻa protease HCV (Ki=14 nM) no ka mālama ʻana i ka maʻi maʻi hepatitis C.ʻO Boceprevir me ka interferon pegylated a me ka ribavirin (PegIFN/RBV) i hiki ai ke hoʻomaikaʻi i nā helu pane virological mau o nā maʻi me ka genotype 1 HCV.Hoʻopili ʻo Boceprevir me ka immunosuppressive therapy (IT) ma ke kāohi ʻana i ka enzyme cytochrome P450 3A.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou